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This study evaluated the theoretical clinical outcome of three marbofloxacin
posology regimens in two groups of pigs (weaners and fatteners) for the treat-
ment of Actinobacillus pleuropneumoniae (App) and Haemophilus parasuis (Hp)
infection and the appearance of resistant bacteria due to the antibiotic treat-
ment. The probability of target attainment (PTA) for pharmacokinetic/phar-
macodynamics (PK/PD) ratios associated with clinical efficacy and with the
appearance of antimicrobial resistance for fluoroquinolones at each minimum
inhibitory concentration (MIC) or mutant prevention concentration (MPC)
were calculated, respectively. The cumulative fraction of response (CFR) was
calculated for the three posology regimens against App and they ranged from
91.12% to 96.37% in weaners and from 93% to 97.43% in fatteners, respec-
tively. In the case of Hp, they ranged from 80.52% to 85.14% in weaners
and from 82.01% to 88.49% in fatteners, respectively. Regarding the PTA of
the PK/PD threshold associated with the appearance of antimicrobial resis-
tance, results showed that marbofloxacin would prevent resistances in most
of the animals up to the MPC value of 1 lg/mL.
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INTRODUCTION
Marbofloxacin is a third generation fluoroquinolone widely
used in veterinary medicine. Its properties of rapid absorption,
good distribution and broad spectrum against most of the
swine respiratory pathogens, such as Haemophilus parasuis (Hp)
and Actinobacillus pleuropneumoniae (App), make it a good can-
didate to deal with a respiratory outbreak due to any of these
pathogens.
The major issues of practitioners when treating a large popu-
lation of animals are to maximize the likelihood of a favourable
clinical outcome at population level and to minimize the
appearance and development of antimicrobial resistance that
could affect future treatments. Pharmacokinetic (PK) and phar-
macodynamic (PD) models are a useful tool to foresee clinical
efficacy and it could be also used to design and choose the
right antimicrobial therapy (Mckellar et al., 2004).
Currently, a great amount of information is available on the
pharmacokinetics and pharmacodynamics of fluoroquinolones
and the relationship between PK and PD parameters that could
be associated with the clinical outcome. The ratios between the
area under the curve during the first 24 h and the minimum
inhibitory concentration (AUC0-24/MIC) and between the maxi-
mum concentration and MIC (Cmax/MIC) correlate well with
successful therapeutic resolution when fluoroquinolones are
used to cope with an infection. Thus, a threshold of AUC0-24/
MIC of >125 h and Cmax/MIC of >10 would correlate with suc-
cessful therapeutic outcome according to literature (Toutain
et al., 2002; Mckellar et al., 2004) for fluoroquinolones. Never-
theless, these ratios would not be the most appropriate for the
prediction of bacterial resistance. In this case, a better marker to
describe the likelihood of appearance of antimicrobial resistance
is the ratio between the AUC0-24 and the mutant prevention
concentration (MPC) (Zhao & Drlica, 2008). Regarding AUC0-
24/MPC, the study of Cui et al. (2006) established that a value of
AUC0-24/MPC above 25 h restricts the acquisition of resistances
in a Staphylococcus aureus infection (a gram-positive bacterium).
Similar values were found by Olofsson et al. (2006), in an
in vitro study, and Ni et al. (2013), in an in vivo study (rabbit
model), where a ratio AUC0-24/MPC>22 h and >20 h were
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established to prevent resistance appearance in the case of a Esc-
herichia coli infection (a gram-negative bacteria), respectively.
The use of Monte Carlo simulation (MCS) takes into account
the variability of the drug PK and the probability distribution of
the bacterial MIC to make predictions of the likely result of differ-
ent therapeutic approaches, using different antimicrobial dosage
regimens. To achieve this goal, it is taken into account the
threshold values for PK/PD parameters that correlate with clini-
cal efficacy (Roberts et al., 2011). Thus, MCS could be a useful
tool to assess and foresee the probability of a favourable outcome
of an antibiotic treatment in a large population of animals. This
same approach could be used to foresee the appearance of the
antimicrobial resistance taking into account the threshold
values for PK/PD parameters associated with this event.
The main objective of this work was to evaluate the usefulness
of three marbofloxacin posology regimens against Hp and App
taking into account their PK and PD variability. Thus, it was
assessed the probability of achieving the threshold PK/PD
parameters associated with clinical efficacy and with the appear-
ance of antibiotic resistance for marbofloxacin in two pig groups
(weaners and fatteners) usually treated with this antibiotic.
MATERIALS AND METHODS
Marbofloxacin PK data and dose selection
Marbofloxacin PK data for weaner and fattener pigs have been
recently published by Schneider et al. (2014) and this informa-
tion have been used with permission of the authors for this
research work. Briefly, marbofloxacin pharmacokinetic parame-
ters were determined using compartmental analysis with the
WinNonlin software version 5.0.1 (Pharsight Corporation, St
Louis, MO. USA) in 10 weaners and seven fattener pigs. Phar-
macokinetic profile fitted better to a bicompartmental and
monocompartmental model for weaners and fatteners, respec-
tively. One animal was excluded from the weaners due to
abnormal values for the simulations.
To carry out the pharmacokinetic and pharmacodynamic eval-
uation, the doses of 2, 4 and 8 mg/kg for marbofloxacin were
selected according to the most frequent posology regimens in use
under field conditions. As previously commented, the pharmaco-
kinetic data came from a previous study with a dose of 8 mg/kg
bw and the data for the 2 and 4 mg/kg bw doses were inferred
taking into account the marbofloxacin dose proportionality as
described by Schneider et al. (2014). It must be highlighted that
these doses are usually applied in different posology regimens in
daily practice (2 mg/kg bw three times each 24 h, 4 mg/kg bw
twice each 48 h and 8 mg/kg bw in one single shot).
Microbiological data
MIC distribution. MIC distribution was extracted from a poster
communication presented at the 4th European Symposium of
Porcine Health Management (ESPHM) in 2012 (Giboin et al.,
2012). MIC was determined as explained elsewhere (Meunier
et al., 2004; Kroemer et al., 2012).
MPC determination. The mutant prevention concentration
(MPC) corresponds to the first antibiotic concentration at
which no bacterium was recovered when 1010 cells were
applied to agar plates containing 2-fold increasing antibiotic
concentration (Blondeau et al., 2001). Simply, a MPC is an
MIC determination with a large inoculum (Mouton et al.,
2005). The MPC was determined as described by Blondeau
et al. (2001) with slight modifications. Briefly, each strain was
grown overnight (20 to 24 h) on ten plates of Mueller Hinton
(MH) agar supplemented with 5% lysed horse blood and
20 lg/mL b-Nicotinamide adenine dinucleotide at 35  2 °C
with 5  2% CO2. Two mL of MH broth was then added to
each plate, spread and pooled to give 20 mL of bacterial
suspension. After a centrifugation for 30 min at 5000 g, the
supernatant was removed and the remaining pellet was
resuspended in 3 mL of MH broth. 0.2 mL of the bacterial
suspension (around 1010 cells) were spread onto
supplemented MH agar plates containing appropriate
marbofloxacin concentrations (0.002–8 lg/mL). Plates were
incubated at 35  2 °C in air supplemented with 5  2%
CO2 and growth observed at 24 and 48 h. MPC was recorded
as the lowest antibiotic concentration that allowed no growth.
Due to the complexity of this determination, it was only
feasible to carry out this determination in six App and two
Hp strains.
PK/PD analysis and Monte Carlo simulation (MCS)
The MCS were performed with Oracle Crystal Ball
V.11.1.2.0.00. (Oracle Corporation, Redwood Shores, CA,
USA). Two sets of simulations were performed, one for the
weaners, using the following formula for the bicompartimental
model after intramuscular administration:
CðtÞ ¼ F D K01
V


K21 a
ðK01 aÞ  ðb aÞ  e
at
þ K21 bðK01 bÞ  ða bÞ  e
bt
 K21 K01ða K01Þ  ðK01 bÞ  e
K01t

where F is the bioavailability, D is the dose of antibiotic admin-
istered, K01 is the absorption rate constant, V is the distribu-
tion volume, K21 is an intercompartmental micro-rate
constant, a and b are elimination macro-rate constants and t
is a given time.
In the case of the fatteners, it was used a monocomparti-
mental model after intramuscular administration:
CðtÞ ¼ F D K01
V ðK01 K10Þ  ðe
K10t  eK01tÞ
where F is the bioavailability, D is the dose of antibiotic admin-
istered, K01 is the absorption rate constant, V is the distribu-
tion volume, K10 is the elimination rate constant and t is a
given time.
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Each simulation set was performed with 10000 simulated
PK profiles. The pharmacokinetic values and adjustments used
in the models are shown in Table 1 for the bicompartmental
model in the case of weaners and in Table 2 for the monocom-
partmental model in the case of fatteners. The weight was esti-
mated in 25 kg for piglets and 55 kg for fatteners. For the
calculations, marbofloxacin concentrations were simulated
over 24 h with a step of 0.1 h. AUC0-24 was calculated using
the linear trapezoidal mode for each one of the simulated PK
profiles.
The following parameters were calculated to foresee the clin-
ical outcome:
a) Probability of target attainment (PTA) (Mouton et al.,
2005) in the simulated population taking into account the PK/
PD threshold values of AUC0-24/MIC>125 h and Cmax/MIC>10
for each MIC point calculated ranging in geometric progression
from 0.002 to 8 lg/mL.
b) The cumulative fraction of response (CFR) (Mouton et al.,
2005). It is the expected population probability to reach the
threshold values of AUC0-24/MIC>125 h or Cmax/MIC>10 tak-
ing into account the probability of the MIC strain distribution.
A CFR≥90% was considered optimal against a bacterial popula-
tion, whereas a CFR ≥80% but ≤90% was associated with
moderate probabilities of success (Bradley et al., 2003). This is
the most practical parameter for practitioners.
Furthermore, the following parameters were calculated to
predict the likelihood of developing resistances in fluoroquinol-
ones as described in the literature by Cui et al. (2006), Drlica
and Zhao (2007) and Zhao and Drlica (2008):
c) PTA in the simulated population of the threshold values
AUC0-24/MPC>25 h for each MPC point ranging in geometric
progression from 0.002 to 8 lg/mL. Other authors pointed
slightly lower AUC0-24/MPC as threshold values (Olofsson
et al., 2006; Ni et al., 2013) but it was chosen a value of
AUC0-24/MPC>25 h as a worst case scenario.
RESULTS
MPC results
MPC were determined against six strains of App with a MIC of
0.03 lg/mL (n = 3) and 0.06 lg/mL (n = 3). Two strains of
Hpp with a MIC of 0.015 and 0.03 lg/mL were also tested.
MPC results are shown in Table 3.
For all App strains (MIC of 0.03 to 0.06 lg/mL), the MPC
were comprised between 0.12 to 0.5 lg/mL, which corre-
sponded to 2- to 8-fold MIC. No mutants were able to grow at
a concentration above 0.5 lg/mL even in strains with reduced
susceptibility. In the case of Hp, MPC were equal to 0.015–
0.06 lg/mL (1- to 2-fold MIC).
PK simulation
The simulated PK profiles, using the mean, maximum and
minimum values obtained from simulations, are presented
in Fig. 1. The mean clearance values that were calculated
from simulations (Tables 1 and 2) were 0.120.11 L/kg/h
(coefficient of variation: 91.6%) for fatteners and
0.090.02 L/kg/h (coefficient of variation: 22%) for weaners,
respectively. These results are in agreement with a clearance
value of 0.120.02 L/kg/h described by Ding et al. (2010).
Furthermore, Schneider et al. (2014) described clearance
values of 0.092 and 0.079 L/kg/h in piglets and fatteners,
respectively.
Table 1. Pharmacokinetic parameters used in the bicompartmental
model for weaners
Parameter Distribution
Distribution parameters
(coefficient of variation%)
Bioavailability (F) Beta PERT Min: 0.87; most likely: 0.93;
max:0.99
Distribution
Volume (Vd)
Log normal X:1.58; SD: 0.23 (14.6)
K01 Log normal X:5.85; SD:0.95 (16.23)
K21 Log normal X:0.18; SD:0.01 (5.55)
a Fixed Value X:0.2115
b Log normal X:0.05; SD:0.01 (20)
K01, absorption rate constant; K21, intercompartmental micro-rate
constant, a, b, elimination rate macro constants, X, average value; SD,
standard deviation; coefficient of variation between brackets.
Table 2. Pharmacokinetic parameters used in the monocompartmental
model for fatteners
Parameter Distribution
Distribution parameters (coefficient
of variation%)
Bioavailability (F) Beta PERT Min: 0.9; Most likely: 0.95; max:1
Distribution
volume (Vd)
Log normal X:1.4; SD: 0.1(7)
K01 Log normal X:5.06; SD:1.8 (35.57)
K10 Log normal X:0.05; SD:0.01 (20)
K01, absorption rate constant; K10, elimination rate constant; X, aver-
age value; SD, standard deviation; coefficient of variation between
brackets.
Table 3. Mutation prevention concentration (MPC) and minimum
inhibitory concentration (MIC) of six App and two Hp strains
Isolate details MIC (lg/
mL)
MPC (lg/mL)
Isolate
number Species
Agar dilu-
tion
Duplicate
1
Duplicate
2
1 A. pleuropneumoniae 0.03 0.25 0.12
2 A. pleuropneumoniae 0.03 0.25 0.12
3 A. pleuropneumoniae 0.03 0.12 0.12
4 A. pleuropneumoniae 0.06 0.25 0.12
5 A. pleuropneumoniae 0.06 0.5 0.12
6 A. pleuropneumoniae 0.06 0.25 0.25
7 H. parasuis 0.015 0.015 0.03
8 H. parasuis 0.03 0.06 0.06
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Clinical outcome
The probability of target attainment (PTA) of the simulated
pig population taking into account a threshold value of AUC0-
24/MIC>125 h for a MIC range from 0.002 to 8 lg/mL of
App and Hp strains to marbofloxacin is shown in Fig. 2. In
this case, the PTA is 100% at the three posology regimen
studied for a MIC lower than 0.06 lg/mL for both bacteria
(App and Hp) and this value is 0% for MIC values higher
than 1 lg/mL in both cases. This PTA value would decrease
from 100% to a value lower than 40% in weaner pigs at MIC
values of 0.12, 0.25 and 0.5 lg/mL for both bacteria at a
dose of 2, 4 and 8 mg/kg bw of marbofloxacin, respectively.
In the case of fatteners, the PTA is 100% at the three posolo-
gy regimen studied for a MIC value lower than 0.12 lg/mL
for both bacteria (App and Hp) and 0% for MIC values higher
than 1 lg/mL for both pathogens. Finally, the PTA value
would decrease from 100% to a value of 0% in fattener pigs
at MIC values of 0.25, 0. 5 and 1 lg/mL for both bacteria at
a dose of 2, 4 and 8 mg/kg bw of marbofloxacin, respectively
(Fig. 2).
The probability of target attainment (PTA) of the simulated
pig population taking into account a threshold value of Cmax/
MIC>10 for App and Hp strains to marbofloxacin is shown in
Fig. 3. The results obtained are almost the same as previously
described (Fig. 2) for the other surrogate marker (AUC0-24/
MIC>125 h) with the particularity that the PTA value would
decrease from 100% at the same MIC points in fattener (60–
80%) than in weaner pigs (20–30%) at 0.12, 0.25 and
0.5 lg/mL for both bacteria at a dose of 2, 4 and 8 mg/kg bw
of marbofloxacin, respectively.
The cumulative fraction of responses (CFRs) of the simulated
pig population for the three posology regimens according to
their probability of MIC strain distribution are shown in
Table 4. The same CFRs values were obtained using AUC0-24/
MIC or Cmax/MIC as surrogate markers. The CFR value was
higher than 91% and 80.5% for App and Hp for all the studied
posology regimens, respectively. Overall, fatteners showed a
slightly better theoretical clinical outcome (CFR value) than
weaners for both bacteria in all the studied posology regimens
reaching the best result at the dose of 8 mg/kg of marbofloxa-
cin in weaners (above 96% for App and 85% for Hp) and
fatteners (97% for App and 88% for Hp).
Appearance of resistances
The probability of target attainment (PTA) of the simulated pig
population taking into account a threshold value of AUC0-24/
MPC>25 h to avoid the appearance of antimicrobial resistance
is shown in Fig. 4.
The PTA of the threshold values for preventing antimicrobial
resistance of AUC0-24/MPC>25 h across different MPC points
(Fig. 4) clearly show that the generation of antimicrobial resis-
tance up to a MPC value of 0.25, 0.5 will be avoided, and
1 lg/mL for both bacteria at a dose of 2, 4 and 8 mg/kg bw of
marbofloxacin in weaners, respectively. However, this genera-
tion will be probably avoided up to a MPC value of 0.5, 1 and
2 lg/mL for both bacteria at a dose of 2, 4 and and 8 mg/kg
bw of marbofloxacin in fatteners, respectively. The same analy-
sis was carried out taking into account the effect of the first
dose (data not shown) and it was not observed any difference
in comparison with the results obtained for the whole posology
regimen.
DISCUSSION
It is widely accepted that drugs are well-designed to cover most
of the bug strain population according to PK parameters deter-
mined in preclinical studies in the target species. However, it
will be very interesting to analyse the probability of success in
any antibiotic treatment and in the generation of antimicrobial
resistance taking into account the pharmacokinetic and phar-
macodynamic variability observed for the pig and micro-organ-
isms, respectively. This type of analysis could be even more
relevant if it is taking on board the presence of a population of
different strains of the same micro-organism in one animal
(Lowe et al., 2012; Vilalta et al., 2012). Finally, this type of
analysis could be relevant to foresee the clinical efficacy
and the generation of antimicrobial resistance in a dynamic
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Fig. 1. Pharmacokinetic profiles depicted using the values of the mean
(square), maximum (triangle) and minimum (circle) values obtained
from the simulations.
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population of micro-organism whose pharmacodynamic prop-
erties are continuously evolving.
In this study, PK/PD simulations were performed to evaluate
three different posology regimens of marbofloxacin, taking into
account the antimicrobial susceptibility of App and Hp and the
pharmacokinetic variability of two different groups of pigs,
weaners and fatteners. The probability of clinical success was
evaluated through the use of the AUC0-24/MIC and Cmax/MIC
index, while the risk of emergence of mutants was evaluated
through the use of AUC0-24/MPC index as surrogate markers.
Although the same procedures used here have been applied on
several occasions to calculate the usefulness of therapeutic
strategies in human medicine (Isla et al., 2011; Cao et al.,
2013; Goff & Nicolau, 2013), there are some limitations that
should be discussed. PK/PD calculations were based on the
total drug concentration on serum. It could be assumed that
marbofloxacin concentration in the site of action, lung and
bronchial secretions, was at least very similar to that observed
in serum due to the high bioavailability, low protein binding
and tissue distribution reported for fluoroquinolones (Martinez
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et al., 2006). Hence, for example, Messenger et al. (2012)
found that the tissue penetration ratio (AUCtissue/AUCplasma) of
enrofloxacin in the pleural cavity in pigs was 1.40  0.35 and
Bimazubute et al. (2009) described a value of 1.26 for the
same ratio in the nasal secretions. In conclusion, it seems very
reasonable to use the available concentration observed in
plasma to foresee the clinical efficacy of this antibiotic. Other
clear limitation of this study is that PK parameters used in this
research work (from a limited number of animals) could not
represent the real interindividual variability of the PK parame-
ters in the targeted animal population not only in healthy ani-
mals but also in sick ones. Thus, as an alternative to the
previous point, when experimental population data are lacking,
the simulations can be performed using ‘a priori’ values of the
interindividual variability that are ‘reasonably’ high enough to
fit with the real situation. This point has been accomplished in
this research work. Thus, the coefficients of variation for mar-
bofloxacin clearance, used during the simulation for fatteners
and weaners, were 90 and 20%, respectively. The variability
used for this parameter is higher than the previously published
by other authors for this molecule (Ding et al., 2010; Schnei-
der et al., 2014). In conclusion, authors believe that the vari-
ability used is reasonable enough and it should not be a
limitation for the extrapolation of the results obtained to the
whole pig population.
This study shows slight differences between the foreseen clin-
ical outcome in late weaners and early fatteners in spite of the
differences observed in the pharmacokinetic in both age groups
(Schneider et al., 2014) when the effect of the usual posology
regimens in use under field conditions (2 mg/kg bw three
times each 24 h, 4 mg/kg bw twice each 48 h and 8 mg/kg
bw in one single shot) was compared. In this sense, it has to
be taken into account that some of the veterinary drugs are
not designed to reach a steady-state. Thus, many drugs are
designed to get their clinical outcome in one, two or three
doses at most with the exemption of the administered orally
through water or food. Therefore, it seems that a ‘classical’
steady-state for many drugs is not reached. An equivalent
parameter of the classical AUC/MIC or AUCss/MIC for those
drugs which do not reach the steady-state would be the AUC0-
∞/MIC as pointed out by some authors (Toutain et al., 2007).
In this research, the period between 0 and 24 h for the three
posology regimes (2, 4 and 8 mg/kg bw) was studied because
it seems that marbofloxacin exerts its higher effect on bacteria
during this period of time according to an in vitro dynamic test
carried with strains of Mannheimia haemolytica and Pasteurella
multocida (Valle et al., 2012). The authors have not found any
other information in veterinary medicine comparing different
posology regimes using the foreseen effect during the first
24 h. It is clear that further research should be carried out in
this matter. On the other hand, other factors besides single or
Table 4. Cumulative fractions of response (CFR) (%) of the threshold
values of AUC0-24/MIC>125 h and Cmax/MIC>10 (between brackets)
for the simulated populations of weaners and fatteners when crossed
with the MIC distribution probability of the different posology regimens:
2 mg/kg bw, 4 mg/kg bw and 8 mg/kg bw of marbofloxacin
A. pleuropneumoniae H. parasuis
Weaners
2 mg/kg bw 91.12 (91.63) 80.52 (80.78)
4 mg/kg bw 93.99 (93.86) 83.19 (82.65)
8 mg/kg bw 96.37 (96.33) 85.1 (85.14)
Fatteners
2 mg/kg bw 93 (92.92) 82.01 (82.27)
4 mg/kg bw 95.72 (95.08) 83.96 (83.32)
8 mg/kg bw 97.43 (97) 88.49 (87.42)
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Fig. 4. Probability of target attainment of the
threshold value of AUC0-24/MPC>25 for
weaners and fatteners in the three posology
regimens: 2 mg/kg bw (circles), 4 mg/kg bw
(triangles) and 8 mg/kg bw (squares).
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multiple doses should be considered when setting the treatment
such as the early or late treatment and consequently the size
of the bioburden at the site of infection (Ferran et al., 2011)
and the MIC or MPC of the offending pathogen. Although,
some studies corroborate the efficacy of the multiple dose regi-
mens to eradicate or control a pathogen (Aliabadi & Lees,
2002; Sidhu et al., 2011; Vilalta et al., 2011), the concept of
an aggressive early treatment seems to be more suitable to
treat infections, reach the PK/PD targets for fluoroquinolones
and prevent mutations (Martinez et al., 2012). Our results
agree with the literature because the best clinical outcome was
foreseen for the 8 mg/kg bw in one single shot. Moreover, sim-
ilar results were obtained using AUC0-24 or Cmax as surrogate
markers of clinical outcome reinforcing that both parameters
could be used for this purpose as it has been published previ-
ously in the literature (Drusano et al., 1993; Mckellar et al.,
2004; Lees, 2013; Papich, 2014).
Similar values were obtained in the three posology regimens
for App and Hp when the effect of preventing resistances was
simulated using the marker AUC0-24/MPC. Thus, it would seem
quite reasonable to use equally any of the three treatments pre-
viously commented. Different opinions can be found in the liter-
ature about this topic, while some authors pointed that the
single high-dose shot of marbofloxacin would reduce the ampli-
fication of resistances (Valle et al., 2012), other authors con-
cluded that the fractionated dose of the same antimicrobial
would be more beneficial to prevent those resistances (Kesteman
et al., 2009). Monte Carlo simulations had not taken into
account other factors that could lead to the amplification of
resistant subpopulations such as the size of the bioburden at the
infection site (Ferran et al., 2011), as commented previously,
biofilm formation or the effect on other bacterial populations, as
the gut flora (Kesteman et al., 2010). Despite these limitations,
it is assumed that an early treatment of a highly concentrated
drug is more likely to minimize and prevent the amplification of
resistances avoiding the growth of the bioburden that could
lead to high bacterial density scenario where mutations are
more likely to occur. In our case, the 8 mg/kg bw of marboflox-
acin in one shot would reach concentrations with a high proba-
bility of being above the MPC and would be a reliable option
when it comes to prevent the amplification of resistances, at
least in the target site. Finally, the results obtained in connec-
tion with the generation of antimicrobial resistance should be
considered preliminary due to the low number of strains
included in the simulation process. This observation is even
more relevant in the case of Hp strains where the MPC value is
equal or slightly higher than the MIC value. For this reason,
additional studies with a higher number of strains are compul-
sory in order to confirm the obtained results.
Practitioners usually have to start a treatment against App
and Hp without knowing the MIC of the causative pathogen.
Thus, the CFR calculated in this study could be a good way to
estimate the potential for a positive clinical outcome in any
herd. To our knowledge, this is one of the first scientific publi-
cations in the veterinary field where this approach is carried
out. In the future, it could be a good way to select the best
antimicrobial to treat an infection following a prudent use of
these drugs. It is important to keep in mind that MIC probabil-
ity distribution of a determined pathogen may vary between
countries and regions and even time. Taking into account the
MIC distribution provided by Vetoquinol marbofloxacin MIC
surveillance program (Giboin et al., 2012), it could be assumed
that a marbofloxacin treatment would achieve a CFR of more
than 90% (ranging from 91 to 97 depending on the dose)
against App and between the range 80–90% against Hp.
Although, the CFR for Hp is lower than the App CFR, marbo-
floxacin would be a reliable option when it comes to treat
infections caused by these pathogens. It would have been very
interesting to assess CFR for the prevention of resistances, but
there is not enough information about MPC and its probability
frequencies distribution.
Veterinarians usually treat large populations of animals
without knowing the MIC of offending bacteria. Although, the
use of CFRs is new in veterinary medicine, it is a used tool in
human medicine to compare treatments and foresee clinical
failure. Knowing the CFRs of the antimicrobials and bugs
should be a good tool to select a treatment and to predict pos-
sible outcomes. Thus, PK-PD analysis and Monte Carlo simula-
tions are highly valuable techniques to maximize the
favourable result of a therapy but further studies are needed to
address this matter.
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